We are live on ! Find out more
PPBT icon

Purple Biotech
PPBT

10 hedge funds and large institutions have $157K invested in Purple Biotech in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

248% more capital inflows, than outflows

Capital inflows: $184K | Capital outflows: $52.8K

67% more funds holding

Funds holding: 6 → 10 (+4)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
10
Holders Change
+4
Holders Change %
+66.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$80.5K
2
Citadel Advisors
Citadel Advisors
Florida
+$47.8K
3
Virtu Financial
Virtu Financial
New York
+$27.7K
4
Two Sigma Securities
Two Sigma Securities
New York
+$22.6K
5
Bruderman Asset Management
Bruderman Asset Management
New York
+$2.52K

Top Sellers

Rank Fund Capital Flow
1
Menta Capital
Menta Capital
California
-$40.3K
2
SM
Sabby Management
Florida
-$10.1K
3
Morgan Stanley
Morgan Stanley
New York
-$2.52K

PPBT Hedge Fund Activity: Q4 2018 in Review

10 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2018, worth a combined $157K — down 30% from $225K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PPBT positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $80.5K. The largest seller was Menta Capital, cutting an estimated $40.3K.

  • 10 institutional investors held Purple Biotech (PPBT) as of Q4 2018, up from 6 in Q3 2018.
  • Funds reported $157K of Purple Biotech stock for Q4 2018, down 30% quarter-over-quarter.
  • 4 funds opened new Purple Biotech positions in Q4 2018 and 0 closed out, a net change of +4 holders.
  • The largest Purple Biotech buyer in Q4 2018 was Susquehanna International Group, an estimated $80.5K added.
  • The largest Purple Biotech seller in Q4 2018 was Menta Capital, an estimated $40.3K sold.

Based on aggregated 13F filings for Q4 2018.